Navigation Links
Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
Date:11/13/2012

tment-emergent adverse event (TEAE) class was infections, with a similar rate observed among patients in the placebo group (12 percent) and patients receiving baricitinib (14 percent).

Over 24 weeks in the combined 2 mg, 4 mg and 8 mg groups, the rate of TEAEs was 64 percent (36 percent mild, 23 percent moderate, 5 percent severe) and the rate of serious adverse events was 5 percent.

There were no opportunistic infections and no deaths reported through week 24. Dose-dependent changes in laboratory tests (hemoglobin, lymphocyte and neutrophil count, low-density lipoprotein and high-density lipoprotein) were observed, with greater changes being observed in the 8 mg baricitinib group than in the 2 mg and 4 mg groups.

Trial Design and Status
This Phase IIb randomized double-blind, placebo-controlled, dose-ranging study, known as JADA, included 301 patients with moderate-to-severe RA with inadequate response to treatment with methotrexate.

In the initial 12-week treatment duration, patients received one of four doses of baricitinib or placebo. In the 12- to 24-week portion of the study, patients initially randomized to placebo or the 1 mg baricitinib dose were re-randomized to receive either 4 mg once daily or 2 mg twice daily for an additional 12 weeks; patients initially randomized to the 2 mg, 4 mg and 8 mg doses continued therapy with those doses. Patients are continuing to participate in the open-label long-term extension phase of the trial.

About JAK Inhibition
There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. These enzymes are critical components of signaling mechanisms used by a number of cytokines and growth factors, including those that are elevated in RA patients. Cytokines such as interleukin-6, -12 and -23 and both type 1 and type 2 interferons signal through the JAK/STAT pathways. Additional JAK-dependent cytokines also have been implicated in a number of inflammatory and autoimmune diseases, suggesting
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... - A new national Labour Market Information (LMI) report ... of new graduates entering the biotech sector. The BioTalent ... New Grads in Biotech," is sponsored in part by ... and features data collected from new graduates that participated ... 2013 to 2015. Among the interesting trends ...
(Date:3/30/2015)... PARK, N.J. , March 30, 2015 /PRNewswire/ ... (PAMORA) under development by Shionogi & Co., Ltd., ... phase III study (COMPOSE I) for the treatment ... chronic non-cancer pain receiving opioid therapy. Study results ... daily) statistically significantly improved the frequency of spontaneous ...
(Date:3/29/2015)... March 29, 2015 Caris Life ... study data showing the presence of PD-1 ... cancer samples. Using Caris Molecular Intelligence®, the ... identified expression of programmed cell death protein-1 ... histology while its ligand (PD-L1) expression was ...
(Date:3/27/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today ... plan in accordance with Securities and Exchange Commission rule ... Neogen Corporation, is a minority owner of this entity ... Herbert does not have control of this entity, ... only for a portion of the shares owned by ...
Breaking Biology Technology:New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Neogen CEO adopts 10b5-1 Trading Plan 2
... today announced that Solomon Steiner, Chairman and CEO of ... Hidden Gems,Conference in New York, NY on October 8th ... a link to a live audio webcast of the,presentation ... http://www.biodel.com . A replay of the presentation will be ...
... Awarded for Chemistry and Automation as well as Immunoassay ... ... 4 Siemens Medical Solutions,Diagnostics, (http://www.siemens.com/diagnostics ), announced ... Systems, (http://www.medassets.com ), a,Group Purchasing Organization (GPO) and ...
... Dillahunty, Vice,President, Intellectual Property of Oncolytics Biotech Inc. (TSX: ... Company at BIO,InvestorForum 2007 on Thursday, October 11 at ... Palace Hotel in San Francisco from October 9-11, 2007. ... is available on the,company,s website at http://www.oncolyticsbiotech.com . ...
Cached Biology Technology:Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007 2MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions 2MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions 3Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007 2
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
(Date:3/23/2015)... OXFORD, Conn. , Mar. 23, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, announces ... a new advertising campaign on CNBC television starting March 30 ... ads will commence airing in New York ... Executive Officer said: "We are excited about our new ad ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... news clip that aired this week on Washington ... In a segment "The Next Great Thing", host ... new way to pay, and ,a really big breakthrough in ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... April 10, 2013, New York, NY A dozen ... advancements in basic and clinical cancer research at this ... 2013. Progress in immunotherapy and epigenetics led the program ... therapy. "With new immunotherapy agents available ...
... at which a child with autism is diagnosed is ... or she exhibits, new research from the University of ... nonverbal communication and repetitive behaviors, were associated with earlier ... study in the April issue of the Journal ...
... Department of Energy,s (DOE) National Renewable Energy Laboratory (NREL) ... of real-world performance from solar facilities across the country. ... Performance and Reliability Clearinghouse (O-SPaRC) will give the private ... public capital. "The O-SPaRC dataset will provide the ...
Cached Biology News:Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR 2In autism, age at diagnosis depends on specific symptoms 2
MOUSE ANTI HUMAN COMPLEMENT SC5B-9...
MOUSE ANTI SIMIAN VIRUS 5 Immunogen: Simian virus 5...
... Beagle serum is collected from fasted Beagle canines ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
MOUSE ANTI BOVINE TROPONIN I...
Biology Products: